Expression of heat shock protein 70 in the tissue of patients with laryngeal squamous cell carcinoma

• Authors: Aleksandra Barańska , Aleksandra Maziarz , Jacek Roliński , Janusz Klatka , Katarzyna Dudzińska-Ćwiek , Jacek Tabarkiewicz
• Languages of publication: EN

Abstracts

EN

Introduction. Laryngeal squamous cell carcinoma (LSCC) is a common type of head and neck malignancy. Because of unsatisfactory results of therapy, development of new strategies for LSCC treatment is needed. It is believed that heat shock protein 70 (HSP70) is involved in pathogenesis of LSCC. Thus, targeting HSP70 seems to be promising strategy for laryngeal cancer treatment. Aim. The aim of the study was to assess the HSP70 concentration in laryngeal squamous cell carcinoma specimens and its correlation with tumor volume and TNM staging. Material and methods. An ELISA method and a Bradford protein assay were used to evaluate the HSP70 concentration in peripheral blood cells, tumor tissue and lymph nodes from the patients suffering from LSCC. Results. We demonstrated that the HSP70 concentration is significantly different between examined compartments. The highest level was observed in peripheral blood, while the lowest was in the lymph nodes. The HSP70 expression was correlated to tumor volume. Conclusion. Our results showed varied expression of HSP70 in tissue from patients with LSCC, but there was no association between HSP70 concentration and TNM staging. Currently, application of HSP70 inhibition as a LSCC treatment could be rather associated with systemic blocking of this molecule than target inhibition in tumor tissue. However, further analysis on a larger group of patients is needed.

Keywords

EN

HSP70; LSCC; treatment

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2019
• Issue: 1
• Pages: 16-21

Contributors

author

Aleksandra Barańska

• Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland

author

Aleksandra Maziarz

• Institute of Experimental and Clinical Medicine, Department of Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

author

Jacek Roliński

• Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland

author

Janusz Klatka

• Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland

author

Katarzyna Dudzińska-Ćwiek

• Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland

author

Jacek Tabarkiewicz

• Institute of Experimental and Clinical Medicine, Department of Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland
• Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland

Identifiers

DOI

10.15584/ejcem.2019.1.3